Quanterix (QTRX) Projected to Post Quarterly Earnings on Monday

Quanterix (NASDAQ:QTRX) is projected to release its results before the market opens on Monday, December 22nd. Analysts expect Quanterix to post earnings of ($0.23) per share for the quarter.

Quanterix (NASDAQ:QTRX) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.13). Quanterix had a negative return on equity of 21.34% and a negative net margin of 73.47%.The company had revenue of $40.23 million during the quarter, compared to analyst estimates of $37.85 million. On average, analysts expect Quanterix to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Quanterix Stock Performance

Shares of QTRX opened at $6.59 on Friday. The company has a 50-day simple moving average of $6.26 and a 200-day simple moving average of $5.78. The firm has a market capitalization of $307.82 million, a P/E ratio of -2.83 and a beta of 1.01. Quanterix has a 52 week low of $4.05 and a 52 week high of $12.41.

Institutional Trading of Quanterix

Institutional investors have recently bought and sold shares of the stock. Millennium Management LLC increased its stake in shares of Quanterix by 9,880.2% in the 3rd quarter. Millennium Management LLC now owns 1,209,199 shares of the company’s stock valued at $6,566,000 after buying an additional 1,197,083 shares during the period. Balyasny Asset Management L.P. boosted its holdings in Quanterix by 1,625.2% in the second quarter. Balyasny Asset Management L.P. now owns 767,801 shares of the company’s stock valued at $5,106,000 after acquiring an additional 723,295 shares during the last quarter. Ameriprise Financial Inc. boosted its holdings in Quanterix by 14.0% in the second quarter. Ameriprise Financial Inc. now owns 4,236,877 shares of the company’s stock valued at $28,175,000 after acquiring an additional 521,639 shares during the last quarter. Marshall Wace LLP acquired a new stake in Quanterix in the second quarter worth about $2,954,000. Finally, Vanguard Group Inc. raised its holdings in Quanterix by 4.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,647,515 shares of the company’s stock worth $14,376,000 after purchasing an additional 118,565 shares during the last quarter. Institutional investors and hedge funds own 86.48% of the company’s stock.

Analyst Ratings Changes

QTRX has been the topic of several research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Quanterix in a research note on Wednesday, October 8th. Wall Street Zen upgraded Quanterix from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th. One research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $10.33.

Quanterix Company Profile

Quanterix Corporation is a life sciences and diagnostics company specializing in ultra-sensitive digital immunoassay platforms. Its proprietary Single Molecule Array (Simoa) technology enables researchers to detect and quantify proteins, peptides and nucleic acids at femtomolar concentrations, offering sensitivity that surpasses traditional immunoassay methods. By translating single-molecule detection into routine laboratory workflows, Quanterix aims to accelerate biomarker discovery and the development of novel diagnostics and therapeutics.

The company’s core product portfolio includes the Simoa HD-1 and HD-X Analyzers, which automate high-throughput digital immunoassays for quantifying low-abundance biomarkers.